论文部分内容阅读
背景:对于临床常用于治疗神经系统病变的脐带源干细胞和骨髓源干细胞的安全性,尚无较为全面研究。目的:比较脐带源和骨髓源干细胞移植治疗神经系统病变的安全性。方法:将214例神经系统病变患者随机分为两组,分别通过局部、静脉、脑脊液循环途径,移植脐带源干细胞或骨髓源干细胞。每例患者植入干细胞(5～12)×108个。结果与结论:两组患者干细胞移植治疗后淋巴细胞计数、谷丙转氨酶、谷草转氨酶、IgA、IgM,与治疗前相比有显著性意义(P<0.01),组间比较差异无显著性意义(P>0.05)。两组患者治疗后脑脊液白细胞和红细胞均出现异常,高于正常值,组间比较差异无显著性意义(P>0.05)。两组患者潘台实验阳性、不良反应发生率组间相比差异无显著性意义(P>0.05)。说明脐带源和骨髓源干细胞移植治疗神经系统病变的安全性无明显差别。
BACKGROUND: There is no comprehensive study on the safety of umbilical cord stem cells and bone marrow-derived stem cells commonly used in clinical treatment of neurological diseases. OBJECTIVE: To compare the safety of umbilical cord stem cells and bone marrow-derived stem cells in the treatment of neurological diseases. Methods: A total of 214 patients with neurological diseases were randomly divided into two groups. Umbilical cord derived stem cells or bone marrow derived stem cells were transplanted through local, intravenous and cerebrospinal fluid circulation respectively. Each patient was implanted with stem cells (5-12) × 108. RESULTS AND CONCLUSION: Lymphocyte counts, alanine aminotransferase, aspartate aminotransferase, IgA and IgM after treatment of stem cell transplantation in both groups were significantly higher than those before treatment (P <0.01), but there was no significant difference between the two groups P> 0.05). The levels of leukocytes and erythrocytes in cerebrospinal fluid were abnormal in both groups after treatment, which were higher than the normal values. There was no significant difference between the two groups (P> 0.05). Pantai test was positive in both groups, the incidence of adverse reactions was no significant difference between groups (P> 0.05). That umbilical cord-derived and bone marrow-derived stem cell transplantation for the treatment of neurological disease no significant difference in safety.